Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer
Case Reports in Oncology · 22.09.2026
DOI: 10.1159/cro/abzag014 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.09.2026. Verfasst von Lahari Ramagiri und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The Ohio State University, Columbus, OH, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Trastuzumab and pertuzumab, in combination with chemotherapy, are first-line anti- human epidermal growth factor 2 (HER2) therapies in the treatment of HER2-positive metastatic breast cancer. Although these therapies have been shown to improve the overall survival of patients, they can also be associated with adverse events; ocular toxicities have not been well-documented. Case Presentation: This report outlines the case of a patient with a spectrum of new-onset transient ocular symptoms on pertuzumab-trastuzumab combination therapy that improved with cessation of the drug and recurred with trastuzumab monotherapy rechallenge. She developed ocular symptoms 2 years into her treatment course. Her principal ophthalmologic diagnosis was dry eye syndrome of bilateral lacrimal glands and keratoconjunctivitis sicca. Ultimately, she opted for close observation in lieu of continuing therapy. Her staging scans show no evidence of disease, and she denies eye-related symptom recurrence.
Conclusion
Given the limited knowledge regarding the long-term ocular adverse events of HER2-targeted therapies, medical oncologists should routinely ask patients about new-onset or worsening ophthalmic symptoms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, The Ohio State University, Columbus, OH, USA.
- Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Zitieren
APA
Ramagiri, L., Johnson, K. C. C., Gatti-Mays, M. E., & Davenport, A. P. (2026). Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer. Case Reports in Oncology. https://doi.org/10.1159/cro/abzag014
Vancouver
Ramagiri L, Johnson KCC, Gatti-Mays ME, Davenport AP. Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer. Case Reports in Oncology. 2026. doi:10.1159/cro/abzag014
BibTeX
@article{Ramagiri2026,
author = {Ramagiri, Lahari and Johnson, Kai C C and Gatti-Mays, Margaret E and Davenport, Ashley P},
title = {Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer},
journal = {Case Reports in Oncology},
year = {2026},
doi = {10.1159/cro/abzag014}
}
EUVIMED